ITOS

Insider Trades

Name	Value	Action	Price	Current Price
Detheux MichelChief Executive Officer $440k43.9k shares SellJun 10, 2025 $10.02 --
Detheux MichelChief Executive Officer $84k8.4k shares SellJun 10, 2025 $10.02 --
Detheux MichelChief Executive Officer $440k43.9k shares SellJun 9, 2025 $10.03 --
Detheux MichelChief Executive Officer $84k8.4k shares SellJun 9, 2025 $10.03 --
Detheux MichelChief Executive Officer $448k43.9k shares SellJun 6, 2025 $10.21 --
Hallal DavidDirector $391k38.2k shares SellJun 6, 2025 $10.24 --

Trade ITOS

About iTeos Therapeutics, Inc.

iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established in 2011, iTeos Therapeutics, Inc. is based in Watertown, Massachusetts.

CEO: Michel Detheux
IPO Date: Jul 24, 2020

Market Data

Open: $10.15
High: $10.15
Low: $10.15
Volume: 11M
52W High: $17.63
52W Low: $4.80

Valuation

Market Cap: $449M
Enterprise Value: $246M

Financials

Free Cash Flow: $-100M
Revenue: $35M
Net Income: $-134M
Cash: $142M
Debt: $5.1M

Events

EarningsAug 6

EPS est. -1.12 · actual -1.51